<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522154</url>
  </required_header>
  <id_info>
    <org_study_id>HDZ-KA_017_MG</org_study_id>
    <nct_id>NCT04522154</nct_id>
  </id_info>
  <brief_title>Transcatheter Tricuspid Valve Interventions and Right Ventricular Function: Evaluation With Magnetic Resonance Imaging</brief_title>
  <official_title>Transcatheter Tricuspid Valve Interventions and Right Ventricular Function: Evaluation With Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an urgent need for transcatheter tricuspid interventions, as pharmaceutical therapy&#xD;
      becomes ineffective in advanced disease stages and surgery remains associated with high&#xD;
      mortality rates. Despite the promising results, in some patients, although good procedural&#xD;
      results were achieved, no clinical improvements were measured. Right ventricular dysfunction&#xD;
      is suspected to be the cause of the failed therapeutic strategy. Therefore this study aims to&#xD;
      analyze right ventricular function with magnet resonance imaging before and 3-months after&#xD;
      the procedure in order to gain insight into the prevalence and dynamics of right ventricular&#xD;
      dysfunction in severe tricuspid regurgitation and to identify possible predictors for&#xD;
      treatment failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on tricuspid annular plane systolic excursion resonance tomography and echocardiography</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on tricuspid annular plane systolic excursion in magnet resonance tomography and echocardiography after of transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on right ventricular basal diameter excursion in resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on right ventricular basal diameter in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on right ventricular stroke volume resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on right ventricular stroke volume in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on right ventricular ejection fraction resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on right ventricular ejection fraction in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on right ventricular global longitudinal strain resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on right ventricular global longitudinal in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on right ventricular fractional area change resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on right ventricular fractional area change in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on tricuspid regurgitant fraction resonance tomography and echocardiography</measure>
    <time_frame>3 Month</time_frame>
    <description>Changes on tricuspid regurgitant fraction in resonance tomography and echocardiography after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Testing with 6 min walking test</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on walked distance after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization rate</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of rehospitalization rate after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of stroke rate after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardiovascular complication</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of death rate due to cardiovascular complications after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on the cardiopulmonary exercise capacity</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on aerobic capacity and endurance using the cardiopulmonary exercise testing (vO2max in milliliter per minute per kilogram)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>MR-TTE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receiving cardiac magnet resonance imaging and echocardiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnet resonance imaging</intervention_name>
    <description>Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure</description>
    <arm_group_label>MR-TTE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe tricuspid regurgitation undergoing transcatheter tricuspid&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with Incompatibility with magnetic resonance imaging or echocardiography&#xD;
&#xD;
          -  Another valve disorder that requires treatment&#xD;
&#xD;
          -  Severe precapillary pulmonary hypertension&#xD;
&#xD;
          -  Unstable angina or percutaneous coronary intervention within the last 30 days&#xD;
&#xD;
          -  Previous pacemaker/defibrillator implantation with intracardiac leads&#xD;
&#xD;
          -  Patients with cardiac cachexia or a life expectancy less then 12 months&#xD;
&#xD;
          -  Allergies to the material used.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammed Gercek, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammed Gercek, Dr. med</last_name>
    <phone>0049571971258</phone>
    <email>mugercek@hdz-nrw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum, NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>NRW</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Gercek, Dr. med</last_name>
      <phone>00495371971258</phone>
      <email>mugercek@hdz-nrw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart and Diabetes Center North-Rhine Westfalia</investigator_affiliation>
    <investigator_full_name>Muhammed Ger√ßek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

